Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour

January 13, 2020 updated by: Burcu Isler, SB Istanbul Education and Research Hospital

Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza

Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.

Study Overview

Study Type

Interventional

Enrollment (Actual)

244

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey, 34098
        • SB Istanbul Training and Research Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients hospitalized at medical departments of the hospital who are on the day of discharge

Exclusion Criteria:

  • Egg ellergy
  • Previous allergic reaction to influenza vaccine
  • Pregnancy
  • Cognitive disability

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Self-benefit arm
A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
Active Comparator: Social-benefit arm
A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vaccine uptake following the introduction of the pamphlet
Time Frame: On the same day, upto 24 hours
Difference in the number of patients in each arm who agree to receive influenza vaccine following the introduction of the pamphlet. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the self-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.
On the same day, upto 24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Vaccine uptake in high and low risk group patients following the introduction of the pamphlet
Time Frame: On the same day, upto 24 hours
Vaccine uptake in high and low risk group patients. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the social-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.
On the same day, upto 24 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 13, 2016

Primary Completion (Actual)

March 25, 2017

Study Completion (Actual)

March 25, 2017

Study Registration Dates

First Submitted

January 12, 2020

First Submitted That Met QC Criteria

January 13, 2020

First Posted (Actual)

January 18, 2020

Study Record Updates

Last Update Posted (Actual)

January 18, 2020

Last Update Submitted That Met QC Criteria

January 13, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Influenza Vaccine

Clinical Trials on Self-benefit message

3
Subscribe